The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. PSA response is the primary end-point and objective responses will be checked as available.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
53
Kaiser Permanente Medical Center
Vallejo, California, United States
Georgia Cancer Specialists
Tucker, Georgia, United States
University of Maryland Medical System
Baltimore, Maryland, United States
prostate cancer
prostate-specific antigen (PSA) response
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Washington University School of Medicine
St Louis, Missouri, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Kaiser Permanente NW Oncology Clinic
Portland, Oregon, United States
Oregon Health & Science University
Portland, Oregon, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
University of Washington
Seattle, Washington, United States